Various glucose-lowering agents, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors, are commonly administered for the treatment of T2DM. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.